Deutsche Bank Aktiengesellschaft Increases Pediatrix Medical Group (NYSE:MD) Price Target to $15.00

Pediatrix Medical Group (NYSE:MD - Free Report) had its target price upped by Deutsche Bank Aktiengesellschaft from $9.00 to $15.00 in a report released on Monday, Benzinga reports. The firm currently has a hold rating on the stock.

Several other analysts also recently weighed in on the stock. UBS Group lifted their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a "neutral" rating in a research report on Friday, August 9th. StockNews.com upgraded Pediatrix Medical Group from a "sell" rating to a "hold" rating in a research report on Wednesday, August 7th. Jefferies Financial Group upgraded Pediatrix Medical Group from a "hold" rating to a "buy" rating and raised their target price for the company from $8.00 to $14.00 in a research report on Thursday, September 26th. Truist Financial lifted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a research note on Monday. Finally, Mizuho increased their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a research note on Monday. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of "Hold" and a consensus target price of $14.10.

Pediatrix Medical Group Stock Performance

MD stock traded down $0.07 during midday trading on Monday, reaching $15.14. The company had a trading volume of 1,194,131 shares, compared to its average volume of 872,924. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87. The stock has a 50 day moving average price of $11.62 and a 200 day moving average price of $9.41. The firm has a market capitalization of $1.30 billion, a PE ratio of -4.82, a P/E/G ratio of 1.91 and a beta of 1.55. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $15.43.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The firm's revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business earned $0.29 EPS. Analysts anticipate that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company's stock, valued at $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO James D. Swift sold 11,100 shares of the firm's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares in the company, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 68,100 shares of company stock worth $701,889 over the last ninety days. Company insiders own 2.00% of the company's stock.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently modified their holdings of MD. nVerses Capital LLC acquired a new stake in Pediatrix Medical Group during the 2nd quarter valued at $31,000. Innealta Capital LLC acquired a new position in Pediatrix Medical Group during the second quarter valued at $33,000. Nisa Investment Advisors LLC lifted its stake in Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock worth $36,000 after acquiring an additional 1,524 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Pediatrix Medical Group in the 2nd quarter worth about $72,000. Finally, CWM LLC boosted its position in Pediatrix Medical Group by 134.0% during the 3rd quarter. CWM LLC now owns 6,427 shares of the company's stock worth $74,000 after acquiring an additional 3,681 shares during the period. Institutional investors and hedge funds own 97.71% of the company's stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.